High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer

NMR in Biomedicine

Volumn 27, Issue 1, 2014, Pages 80-89

  Kumar, Virendra ^a   Dwivedi, Durgesh K ^a   Jagannathan, Naranamangalam R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Body fluid; Choline; Citrate; in vitro; Metabolomics; NMR spectroscopy; Prostate cancer; Spermine; Tissue extract

Indexed keywords

CHOLINE; CITRATE; IN-VITRO; METABOLOMICS; PROSTATE CANCERS; SPERMINE; TISSUE EXTRACTS;

BIOMOLECULES; BODY FLUIDS; DISEASES; HISTOLOGY; METABOLISM; METABOLITES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SPECTROSCOPIC ANALYSIS; UROLOGY;

TISSUE;

BIOLOGICAL MARKER; TISSUE EXTRACT;

ARTICLE; BODY FLUID; CARBON NUCLEAR MAGNETIC RESONANCE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; TISSUES; TRANSURETHRAL RESECTION;

BODY FLUID; CHOLINE; CITRATE; IN VITRO; METABOLOMICS; NMR SPECTROSCOPY; PROSTATE CANCER; SPERMINE; TISSUE EXTRACT;

BODY FLUIDS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890865912     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2979     Document Type: Article

References (81)

1. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002; 90: 162-173.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur. Urol. 2012; 61: 1079-1092.
3. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer, 2000; 85: 60-67.
4. Pal RP, Maitra NU, Mellon JK, Khan MA. Defining prostate cancer risk before prostate biopsy. Urol. Oncol. 2012: PMID: 22795499. Epub ahead of print.
5. Ukimura O, Coleman JA, de la Taille A, Emberton M, Epstein JI, Freedland SJ, Giannarini G, Kibel AS, Montironi R, Ploussard G, Roobol MJ, Scattoni V, Jones JS. Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur. Urol. 2013; 63: 214-230.
6. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 2003; 50: 944-954.
7. 13C NMR spectroscopy of the human prostate. Magn. Reson. Med. 1988; 8: 224-230.
8. 13C NMR spectroscopy. Magn. Reson. Med. 1988; 7: 384-411.
9. 31P magnetic resonance spectroscopy. J. Urol. 1993; 150: 2019-2024.
10. 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia. Magn. Reson. Med. 2011; 65: 911-913.
11. 1H NMR. Magn. Reson. Med. 1992; 25: 140-147.
12. 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn. Reson. Med. 1993; 29: 285-291.
13. 1H magnetic resonance spectra. Cancer Res. 1997; 57: 3398-3401.
14. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000; 10: 153-159.
15. Swindle P, McCredie S, Russell P, Himmelreich U, Khadra M, Lean C, Mountford C. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 2003; 228: 144-151.
16. Swindle P, Ramadan S, Stanwell P, McCredie S, Russell P, Mountford C. Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology. MAGMA 2008; 21: 423-434.
17. 1H nuclear magnetic resonance spectroscopically determined citrate in human seminal fluid accompanies the development of prostate adenocarcinoma. J. Urol. 2005; 173: 433-438.
18. 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection. J. Urol. 2006; 176: 2274-2279.
19. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008; 68: 620-628.
20. Lynch MJ, Nicholson JK. Proton MRS of human prostatic fluid: correlations between citrate, spermine, and myo-inositol levels and changes with disease. Prostate 1997; 30: 248-255.
21. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991; 18: 25-46.
22. Franklin RB, Costello LC. Intermediary energy metabolism of normal and malignant prostate epithelial cells. In: Naz RK (ed.). Prostate: Basic and Clinical Aspects. CRC Press: New York; 1997, pp. 115-150.
23. Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000; 59: 269-282.
24. Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 143-153.
25. Marberger H, Marberger E, Mann T, Lutwak-Mann C. Citric acid in human prostatic secretion and metastasizing cancer of prostate gland. Br. Med. J. 1962; 1: 835-836.
26. Awwad HM, Geisel J, Obeid R. The role of choline in prostate cancer. Clin. Biochem. 2012; 45: 1548-1553.
27. Jagannathan NR, Kumar V, Kumar R, Thulkar S. Role of magnetic resonance methods in the evaluation of prostate cancer: an Indian perspective. MAGMA 2008; 21: 393-407. Erratum in: MAGMA, 2008; 21: 2409.
28. Jackson AS, Reinsberg SA, Sohaib SA, Charles-Edwards EM, Jhavar S, Christmas TJ, Thompson AC, Bailey MJ, Corbishley CM, Fisher C, Leach MO, Dearnaley DP. Dynamic contrast-enhanced MRI for prostate cancer localization. Br. J. Radiol. 2009; 82: 148-156.
29. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn. Reson. Med. 2005; 53: 249-255.
30. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62: 140-147.
31. Li X, Priest RA, Woodward WJ, Tagge IJ, Siddiqui F, Huang W, Rooney WD, Beer TM, Garzotto MG, Springer CS Jr. Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection. Magn. Reson. Med. 2012; 69: 171-178.
32. Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, Choyke PL, Harisinghani M. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Am. J. Roentgenol. 2012; 198: 1277-1288.
33. Kurhanewicz J, Vigneron DB. Advances in MR spectroscopy of the prostate. Magn. Reson. Imaging Clin. N. Am. 2008; 16: 697-710, ix-x.
34. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur. J. Radiol. 2007; 63: 351-360.
35. Kumar V, Jagannathan NR, Thulkar S, Kumar R. Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer. Int. J. Urol. 2012; 19: 602-613.
36. Klomp DW, Scheenen TW, Arteaga CS, van Asten J, Boer VO, Luijten PR. Detection of fully refocused polyamine spins in prostate cancer at 7T. NMR Biomed. 2011; 24: 299-306.
37. Chitkara M, Westphalen A, Kurhanewicz J, Qayyum A, Poder L, Reed G, Coakley FV. Magnetic resonance spectroscopic imaging of benign prostatic tissue: findings at 3.0T compared to 1.5T - initial experience. Clin. Imaging 2011; 35: 288-293.
38. Beckonert O, Coen M, Keun HC, Wang Y, Ebbels TM, Holmes E, Lindon JC, Nicholson JK. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 2010; 5: 1019-1032.
39. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007; 2: 2692-2703.
40. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 1994; 35: 606-613; discussion 604-613.
41. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed. 1994; 7: 181-194.
42. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004; 4: 551-561.
43. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12: 413-439.
44. Nicholson JK, Wilson ID. High resolution proton magnetic resonance spectroscopy of biological fluids. Prog. Nucl. Magn. Reson. Spectrosc. 1989; 21: 449-501.
45. Reo NV. NMR-based metabolomics. Drug Chem. Toxicol. 2002; 25: 375-382.
46. Cheng LL, Lean CL, Bogdanova A, Wright SC Jr, Ackerman JL, Brady TJ, Garrido L. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn. Reson. Med. 1996; 36: 653-658.
47. 1H NMR spectroscopy at 9.4T. FEBS Lett. 2001; 494: 112-116.
48. DeFeo EM, Wu CL, McDougal WS, Cheng LL. A decade in prostate cancer: from NMR to metabolomics. Nat. Rev. Urol. 2011; 8: 301-311.
49. 1H nuclear magnetic resonance analysis of intact prostatic hyperplastic and tumour tissues. Anal. Commun. 1998; 35: 113-115.
50. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn. Reson. Med. 1996; 35: 194-200.
51. Yacoe ME, Sommer G, Peehl D. In vitro proton spectroscopy of normal and abnormal prostate. Magn. Reson. Med. 1991; 19: 429-438.
52. 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn. Reson. Med. 1992; 24: 123-136.
53. 1H-NMR spectroscopy. NMR Biomed. 2002; 15: 37-44.
54. Glonek T, Kopp SJ, Kot E, Pettegrew JW, Harrison WH, Cohen MM. P-31 nuclear magnetic resonance analysis of brain: the perchloric acid extract spectrum. J. Neurochem. 1982; 39: 1210-1219.
55. Lin CY, Wu H, Tjeerdema RS, Viant MR. Evaluation of metabolite extraction strategies from tissue samples using NMR metabolomics. Metabolomics 2007; 3: 55-67.
56. 31P NMR at different compositions of the solvent system chloroform-methanol-water. Magn. Reson. Med. 1992; 26: 46-59.
57. Lynch MJ, Masters J, Pryor JP, Lindon JC, Spraul M, Foxall PJ, Nicholson JK. Ultra high field NMR spectroscopic studies on human seminal fluid, seminal vesicle and prostatic secretions. J. Pharm. Biomed. Anal. 1994; 12: 5-19.
58. Bell JD, Brown JC, Sadler PJ. NMR studies of body fluids. NMR Biomed. 1989; 2: 246-256.
59. Lindon J, Nicholson J. Biofluids studied by NMR. Encyclopedia Spectrosc. Spectrom. 1999; 1: 98-116.
60. Lindon JC, Nicholson JK, Everett JR. NMR spectroscopy of biofluids. Annu. Rep. NMR Spectrosc. 1999; 38: 1-88.
61. Metz CE. Basic principles of ROC analysis. Semin. Nucl. Med. 1978; 8: 283-298.
62. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev. Vet. Med. 2000; 45: 23-41.
63. Andrew E, Bradbury A, Eades R. Removal of dipolar broadening of nuclear magnetic resonance spectra of solids by specimen rotation. Nature 1959; 183: 1802-1803.
64. Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol. Cancer Res. Treat. 2004; 3: 591-598.
65. 1H HR-MAS spectroscopy. Magn. Reson. Med. 2006; 55: 1257-1264.
66. Ratiney H, Albers MJ, Rabeson H, Kurhanewicz J. Semi-parametric time-domain quantification of HR-MAS data from prostate tissue. NMR Biomed. 2010; 23: 1146-1157.
67. Levin YS, Albers MJ, Butler TN, Spielman D, Peehl DM, Kurhanewicz J. Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn. Reson. Med. 2009; 62: 1091-1098.
68. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005; 65: 3030-3034.
69. Taylor JL, Wu CL, Cory D, Gonzalez RG, Bielecki A, Cheng LL. High-resolution magic angle spinning proton NMR analysis of human prostate tissue with slow spinning rates. Magn. Reson. Med. 2003; 50: 627-632.
70. Zektzer AS, Swanson MG, Jarso S, Nelson SJ, Vigneron DB, Kurhanewicz J. Improved signal to noise in high-resolution magic angle spinning total correlation spectroscopy studies of prostate tissues using rotor-synchronized adiabatic pulses. Magn. Reson. Med. 2005; 53: 41-48.
71. Wu CL, Taylor JL, He W, Zepeda AG, Halpern EF, Bielecki A, Gonzalez RG, Cheng LL. Proton high-resolution magic angle spinning NMR analysis of fresh and previously frozen tissue of human prostate. Magn. Reson. Med. 2003; 50: 1307-1311.
72. Burns MA, Taylor JL, Wu CL, Zepeda AG, Bielecki A, Cory D, Cheng LL. Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning. Magn. Reson. Med. 2005; 54: 34-42.
73. Maxeiner A, Adkins CB, Zhang Y, Taupitz M, Halpern EF, McDougal WS, Wu CL, Cheng LL. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate 2010; 70: 710-717.
74. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG. Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. 2010; 23: 391-398.
75. Cavaliere B, Macchione B, Monteleone M, Naccarato A, Sindona G, Tagarelli A. Sarcosine as a marker in prostate cancer progression: a rapid and simple method for its quantification in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry. Anal. Bioanal. Chem. 2011; 400: 2903-2912.
76. Jiang Y, Cheng X, Wang C, Ma Y. Quantitative determination of sarcosine and related compounds in urinary samples by liquid chromatography with tandem mass spectrometry. Anal. Chem. 2010; 82: 9022-9027.
77. Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One 2011; 6: e22486.
78. Stenman K, Hauksson JB, Grobner G, Stattin P, Bergh A, Riklund K. Detection of polyunsaturated omega-6 fatty acid in human malignant prostate tissue by 1D and 2D high-resolution magic angle spinning NMR spectroscopy. MAGMA 2009; 22: 327-331.
79. 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 2008; 60: 510-516.
80. Roberts MJ, Schirra HJ, Lavin MF, Gardiner RA. Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J. Urol. 2011; 52: 79-89.
81. Wu CL, Jordan KW, Ratai EM, Sheng J, Adkins CB, Defeo EM, Jenkins BG, Ying L, McDougal WS, Cheng LL. Metabolomic imaging for human prostate cancer detection. Sci. Transl. Med. 2010; 2: 16ra18.